Testing AGA2115 for Osteogenesis Imperfecta in Chinese Patients
Part of Bones, joints & muscles, Genetic & congenital, Skin clinical trials.
This study tests a new medicine called AGA2115 in adults and teenagers with osteogenesis imperfecta (brittle bone disease). The trial aims to find the right dose and see if it can strengthen bones and reduce fracture risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have osteogenesis imperfecta type I, III, or IV confirmed by genetic testing (COL1A1 or COL1A2 gene mutations)
- Your bone density is below normal (measured by a scan called DEXA)
- You are between 12 and 75 years old
- You have not taken certain bone-strengthening medications recently (bisphosphonates in past 6 months, denosumab in past 2 years, or other similar drugs)
- You do not have vitamin D deficiency or other hormone imbalances affecting bone health
- You are not pregnant, breastfeeding, or planning to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AGA2115 for people with osteogenesis imperfecta (also known as brittle bone disease) who have a confirmed genetic change in the COL1A1 or COL1A2 genes. The study aims to see if the drug can help strengthen bones and reduce fracture risk.
This study looks at heart structure and function in children and adults with osteogenesis imperfecta (OI), a condition that affects bones. Researchers want to understand how OI may impact the heart.
This study tests an oral medicine (ABSK061) to see if it can safely improve growth in children with achondroplasia. It is a phase 1/2 trial, meaning it is early research to find the right dose and check for benefits.
This trial tests a new artificial bone material to help heal small bone gaps in the arms or legs. It may help people who need bone grafting after injury or surgery.
This trial uses scans like X-rays, CT, or MRI to study how bones and joints age. It aims to understand aging-related problems and may help develop better ways to detect or treat them.
This trial tests whether mesenchymal stem cells (special cells that can become bone) can help children with severe osteogenesis imperfecta (brittle bone disease) by improving bone strength and growth. It is for children aged 3 to 9 who have a confirmed gene change and have already been treated with pamidronate for at least a year.
Hear when a new Osteogenesis Imperfecta (OI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.